

Company Overview

CNS Pharmaceuticals is a pre-clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic brain and central nervous system tumors. Its lead candidate Berubicin is for the treatment of glioblastoma, a type of brain cancer currently considered incurable, as well as pancreatic and ovarian cancers, and lymphomas. The Company entered into an IP agreement with Houston Pharmaceuticals, Inc. and a Purchase Agreement with Reata Pharmaceuticals Inc.

CNS Pharmaceuticals Continues to Execute on Corporate, Clinical and Regulatory Strategies to Drive Berubicin Towards Commercialization for the Treatment of GBM

Jul 1 2021, 9:05 AM EDT

FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

Jun 29 2021, 8:35 AM EDT

CNS Pharmaceuticals Announces Inclusion in the Russell 2000® Index

Jun 17 2021, 9:05 AM EDT

Investor Relations

IR@cnspharma.com

Management Team

John M. Climaco

Chairman of the Board and Chief Executive Officer

Christopher S. Downs

Chief Financial Officer

Sandra L. Silberman

Chief Medical Officer

Donald Picker

Chief Science Officer

CNS Pharmaceuticals, Inc.

2100 West Loop South
Suite 900
Houston, TX 77027

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.